^
    Back
    Association details:
    Biomarker:PD-L1 overexpression
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:Imfinzi (durvalumab) (PD-L1 inhibitor) +
    Imjudo (tremelimumab-actl) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    PD-L1 ≥50% First-Line Therapy....The following regimens added as Other Recommended...Tremelimumab-actl + durvalumab + carboplatin + albumin-bound paclitaxel (category 2B)...Tremelimumab-actl + durvalumab + (carboplatin or cisplatin) + pemetrexed (nonsquamous) (category 2B).
    Secondary therapy:
    carboplatin; cisplatin; pemetrexed; carboplatin + albumin-bound paclitaxel